Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Vijay Reddy,Zaid Al-Kadhimi ,Hillard M Lazarus ,Patrick J Stiff,Rajneesh Nath,Partow Kebriaei,Koen Van Besien,Hannah Choe ,John M Pagel,Johnnie J Orozco ,Ben K Tomlinson ,Mark S Berger,Edward Agura,George L Chen,Moshe Levy ,Boglarka Gyurkocza,Mark R Litzow ,Sergío Giralt ,Sunil Abhyankar,Mitchell Sabloff,Stuart Seropian,James M Foran,Parameswaran Hari

doi:10.1182/blood-2019-122776

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Vijay Reddy, Zaid Al-Kadhimi + Show 21 more

Open Access

https://doi.org/10.1182/blood-2019-122776

Copy DOI

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Full Text